首页 | 本学科首页   官方微博 | 高级检索  
检索        

百乐眠治疗焦虑症的疗效与安全性Meta分析
引用本文:夏娟,陈其文,邓青龙,唐富荣,杨忍忍,王继伟,余金明.百乐眠治疗焦虑症的疗效与安全性Meta分析[J].神经疾病与精神卫生,2017,17(4):261-266.
作者姓名:夏娟  陈其文  邓青龙  唐富荣  杨忍忍  王继伟  余金明
作者单位:1. 200032,复旦大学公共卫生学院临床流行病学研究中心 公共卫生安全教育部重点实验室健康行为与健康教育教研室;2. 200032 复旦大学公共卫生学院临床流行病学研究中心 公共卫生安全教育部重点实验室健康行为与健康教育教研室;复旦大学附属肿瘤医院中西医结合科
摘    要:目的 评价百乐眠治疗躯体性疾病患者焦虑症的疗效、安全性及与疗程的关系.方法 检索截止到2016年12月在中国知网(CNKI)、万方数据库、中国优秀硕士/博士学位论文数据库、维普中文科技期刊数据库(VIP)、Cochrane图书馆、PubMed、EMBASE、中国学术会议论文数据库中发表的百乐眠治疗焦虑症文献,用Cochrane风险偏倚评估工具评价文献质量,用Stata 14.0和RevMan软件进行Meta分析.结果 纳入文献12篇,患者共1060例,其中试验组536例,对照组524例.总体有效率RR(95%CI)=1.33(1.21~1.45),HAMA评分SMD(95%CI)=-0.36(-0.65~-0.07),不良反应率RR(95%CI)=0.42(0.26~0.70).治疗2,4,8,12周的有效率RR(95%CI)分别为1.34(1.16~1.54),1.24(1.07~1.45),1.36(1.15~1.60)、1.50(1.06~2.13);治疗2,4,8周HAMA评分的SMD(95%CI)分别为-0.96(-1.85~-0.06),-0.28(-0.70~0.14),-0.75(-1.36~-0.13);治疗4,8周的不良反应发生率RR(95%CI)分别为0.25(0.09~0.69),0.41(0.19~0.91).结论 百乐眠胶囊对于改善躯体性疾病患者焦虑症状的总体有效率疗效显著,随着用药疗程的增加其治疗有效率优势越显著,且具有较高的安全性,值得在临床上进一步推广使用.

关 键 词:Meta分析  百乐眠  焦虑症  疗程

Efficacy and safety on Bailemian therapy for anxiety: a meta-analysis
Abstract:Objective To evaluate the relationship among the course,efficacy and safety on Bailemian therapy for anxiety in patients with somatic disease. Methods We retrieved the China journal full-text database(CNKI),Wanfang database,China's outstanding master's/doctoral dissertation database,VIP science and technology periodical database,Cochrane library,PubMed,EMBASE and Chinese academic conference papers,collected and selected related literatures published before Dec,2016 on Bailemian therapy for anxiety. The Cochrane Collaboration's tool,Stata and RevMan software were used for data analysis. Results Twelve literatures including 1060 patients (536 in treatment group,524 in control group) were included. The combined RR(95%CI) were 1.33(1.21-1.45) for efficiency and 0.42(0.26-0.70) for adverse-event. The difference of HAMA between Bailemian and the control group was significantSMD=-0.36(-0.65- -0.07)]. The merged RR(95%CI) of effi-ciency were 1.34(1.16-1.54),1.24(1.07-1.45),1.36(1.15-1.60),1.50(1.06-2.13) respectively,for the treat-ment of 2 weeks,4 weeks,8 weeks and 12 weeks. The merged SMD(95%CI) were -0.96(-1.85- -0.06),-0.28 (-0.70-0.14) and -0.75(-1.36- -0.13) for the treatment of 2 weeks,4 weeks and 8 weeks respectively. And the RR(95%CI) of adverse events in the course of 4 and 8 weeks were 0.25(0.09-0.69) and 0.41(0.19-0.91). Conclusions Bailemian capsule is effective and safety to improve the symptoms of anxiety in patients with so-matic disease. The longer the courses is,the more significant of the efficacy on Bailemian therapy for anxiety is. It might be worth further popularizing in clinical use.
Keywords:Meta-analysis  Bailemian capsule  Anxiety  Treatment course
本文献已被 万方数据 等数据库收录!
点击此处可从《神经疾病与精神卫生》浏览原始摘要信息
点击此处可从《神经疾病与精神卫生》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号